AN2 Therapeutics, Inc.·4

Jan 14, 5:06 PM ET

Marks Gilbert Lynn 4

4 · AN2 Therapeutics, Inc. · Filed Jan 14, 2026

Insider Transaction Report

Form 4
Period: 2026-01-12
Transactions
  • Award

    Common Stock

    [F1]
    2026-01-12+11,56075,309 total
Footnotes (1)
  • [F1]Represents shares issued in lieu of cash compensation under the issuer's non-employee director compensation policy. All shares vest immediately.
Signature
/s/ Lucy Day, Attorney-in-Fact for Gilbert Lynn Marks|2026-01-14

Documents

1 file
  • 4
    ownership.xmlPrimary

    4